Over-the-counter (OTC) biotin (vitamin B 7 ) sales have increased due to perceived health and cosmetic benefits at doses of 5 to 10 mg/d, which are more than 150 times the Adequate Intake recommendation.
Results: Daily biotin ingestion (10 mg) and studies simulating daily biotin use resulted in significant interference in the Gen5 cardiac troponin T (cTnT) assay; the contemporary Gen 4 cTnT and high-sensitivity cardiac troponin I (hs-cTnI) assays were unaffected. The biotin interference threshold was
, and more than 2,000 ng/mL for Gen5 cTnT, cTnT, and hs-cTnI assays, respectively. Streptavidin pretreatment blocked biotin interference in cTn assays.
Conclusions: Biotin interference is possible at plasma concentrations achievable by ingestion of over-the-counter supplements that may lead to delayed or missed diagnosis of myocardial injury with the Gen5 cTnT assay.
Over-the-counter (OTC) biotin (vitamin B 7 ) sales have increased due to perceived health and cosmetic benefits at doses of 5 to 10 mg/d, which are more than 150 times the Adequate Intake recommendation.
1,2 Individuals may be unaware they are taking biotin as it is sold under various commercial names. 3 Very high doses of biotin up to 300 mg/d are currently under investigation as a therapy for multiple sclerosis. 4, 5 Plasma biotin can interfere in immunoassays that have a streptavidin-biotin interaction step. 1, 6, 7 As a result, several routine assays are susceptible to biotin interference, including cardiac troponin (cTn) assays. 1 Biotin interference can lead to either overestimation or underestimation in test results depending on the assay design.
Sandwich immunoassays are a common format for detecting proteins, such as cTn, relying on two antibodies of different epitopes: one capture antibody that has been biotinylated and one antibody coupled to a reporter molecule. The cTn-antibody complexes can then be bound to immobilized streptavidin, washed, and subjected to a detection reaction. For cTn assays relying on this format, excess biotin could bind the streptavidin, thereby blocking binding of the cTn-antibody complexes. Thus, biotin interference can potentially result in missed diagnosis of myocardial injury, including myocardial infraction (MI), due to underestimation.
Consequently, the US Food and Drug Administration (FDA) issued a safety warning on biotin interference in diagnostic tests. 3 A number of recent studies have demonstrated how biotin can affect laboratory testing, particularly thyroid function tests. 1, 6, [8] [9] [10] [11] [12] Accordingly, manufacturers advise a washout period of several hours to weeks prior to sample collection. For critical and time-sensitive tests such as cTn, the biomarkers of myocardial injury, a washout period is not feasible. 1, 8, 13 The fifth-generation cardiac troponin T (cTnT) assay (Gen 5 Stat cTnT; Roche Diagnostics), marketed by Roche as a high-sensitivity (hs)-cTnT assay, is clinically available in the United States. The Gen 5 cTnT assay offers the advantage over many contemporary cTnT and cardiac troponin I (cTnI) assays for safely and rapidly ruling out acute MI within 3 hours of presentation. [14] [15] [16] [17] This potential for faster triage is an attractive option for emergency departments (EDs). We note the distinction between the FDA-cleared Gen 5 cTnT assay vs the hs-cTnT assay Roche markets worldwide as high sensitivity for two reasons. First, the Gen 5 assay and the high-sensitivity assay have different assay characteristics as published in their package inserts to customers. Second, by International Federation of Clinical Chemistry (IFCC) definition, while both the Gen 5 and high-sensitivity assays are excellent assays for clinical use, neither meet the IFCC guideline criteria as a high-sensitivity assay, as neither assay is able to provide measurable concentrations above the limit of detection in 50% or more of women. 18 The Gen 5 cTnT and contemporary Gen 4 cTnT assays are biotinylated assays, rendering them susceptible to biotin interference. 19 Given the critical importance of the Gen5 cTnT assay in rapidly assessing acute MI, we evaluated the biotin tolerance threshold of this assay and the potential impact of biotin interference in patients seeking treatment for chest pain at the ED. [20] [21] [22] [23] Methods to overcome biotin interference using magnetic streptavidin microparticles have been described. 24, 25 We also demonstrate a possible method to overcome biotin interference for cTn using streptavidin-agarose beads.
Materials and Methods
We conducted four studies to evaluate the effects of plasma biotin on cTn measurement. We compared the Gen 5 cTnT assay with a contemporary cTnT assay (Roche Diagnostics) and a research-based hs-cTnI assay (Abbott STAT; Abbott Diagnostics), which is currently clinically available worldwide outside the United States. The hs-cTnI assay is a chemiluminescent microparticle immunoassay devoid of biotin interference. In contrast, the Gen 5 cTnT and contemporary cTnT assays are sandwich immunoassays based on a streptavidin-biotin interaction step that can be susceptible to false-negative interference from biotin. All assays were performed on either the Roche cobas e or Abbott Architect platforms using calibrators and controls per the manufacturer's instructions. Plasma samples were collected in lithium heparin tubes and were stored at +4°C prior to analysis. Samples that were analyzed on the cTnI assay had been frozen at -20°C and thawed prior to analysis. Each of the studies was approved by the University of Texas Southwestern Medical Center institutional review board. For the study of biotin ingestion in healthy volunteers, informed consent was obtained. For studies on excess, discarded, deidentified plasma samples from the ED, informed consent was waived.
The 99th percentile upper reference limits of 19 ng/L (Gen 5 cTnT), 0.01 µg/L (cTnT), and 26 ng/L (hs-cTnI) were used as reference ranges. Values below the lower limit of detection of less than 6 ng/L (Gen 5 cTnT), less than 0.01 µg/L (cTnT), and less than 5 ng/L (hs-cTnI) were considered for rule-out of MI. Significant interference was defined as 10% or more decrease in measured cTn levels in the presence of biotin.
Consumption of OTC Biotin in Healthy Volunteers
In the first study, five healthy volunteers older than 18 years (four women, one man; mean age, 45 years), on no medications or supplements, consumed OTC biotin (Nature Made) 10 mg/d for 5 days after providing informed consent. Plasma samples were obtained at baseline and on day 5 within 2 hours of the last biotin dose; biotin and cTn levels were then measured. Plasma specimens were sent to Mayo Medical Laboratories to estimate biotin levels using a microbiologic-based growth assay. Since the reported upper reference limit for this biotin test was 3,004 pg/mL, plasma specimens were diluted 100-fold in pooled plasma prior to measurement, and the estimated biotin concentration was calculated using a dilution factor of 100. Since cTn levels were below the limit of detection in these healthy participants, a cTn recovery experiment was performed by mixing 270 µL of each participant's plasma with 30 µL of known concentration of cTn with an expected final Gen 5 cTnT concentration of approximately 65 ng/L. For this experiment, only the Gen 5 cTnT and contemporary cTnT assays were available.
Simulation of Biotin Ingestion in Troponin-Positive Patients
Next, we simulated a scenario in which patients took biotin 10 mg/d for 5 days. Based on published pharmacokinetic data, we estimated that at 1, 2, and 4 hours after the last biotin dose, plasma biotin concentrations of 140, 100, and 50 ng/mL could be achieveable. 13, 26 We added these biotin concentrations to plasma specimens from 23 deidentified, discarded, cTn-positive samples from patients referred from the ED for clinical cTn measurement. Both Gen 5 cTnT and cTnT were measured on the biotin-spiked samples. An additional 16 cTnT-positive samples from the ED were evaluated in a similar experiment for the comparison of biotin interference of Gen 5 cTnT and hs-cTnI assays.
Assessment of Thresholds for Biotin Interference of Troponin Assays
We examined the effect of a range of plasma biotin concentrations up to 2,000 ng/mL in pooled cTn-positive patient samples from the ED at five different Gen 5 cTnT levels (17-2,809 ng/L) and determined the lowest biotin concentration that may cause significant interference as recommended by the FDA for all three cTn assays. We prepared a stock solution of 20 mg biotin (cat. B0301; Sigma-Aldrich) with 0.01 N NaOH and then diluted these samples to working stocks in normal saline. We spiked the working stocks into plasma samples to achieve biotin concentrations ranging from 10 to 2,000 ng/mL. We spiked an equal volume of normal saline into no-biotin control samples. To plot the results on the same graph, data were normalized by subtracting the minimum limit of detection from each result and transforming the data to a percentage of the no-biotin controls. Data were fitted to a normalized, nonlinear regression model in GraphPad Prism, Version 7 (GraphPad Software). Concentrations that gave more than a 10% decrease in cTn baseline values (IC 10 ) were calculated from the model.
Blocking Biotin Present in Samples
In the final experiment, we evaluated the effectiveness of streptavidin pretreatment in blocking biotin present in patient samples. We added 50 µL agarose-streptavidin beads (cat. 20347; Pierce ThermoFisher) to 950 µL pooled cTnT-positive ED (n = 3 separate pools) patient samples spiked with known concentrations of biotin (100 and 500 ng/mL) and incubated these at room temperature for 1 hour with intermittent shaking. After centrifugation, we tested the supernatant from these samples with the Gen 5 cTnT and hs-cTnI assays.
Results

Consumption of OTC Biotin in Healthy Volunteers
Serum biotin levels increased in volunteers after consuming a 10-mg/d dose ❚Figure 1❚. As expected, there was no detectable troponin by the contemporary cTnT and Gen 5 cTnT assays in baseline and postbiotin samples among the five healthy participants taking biotin (❚Figure 2❚, black bars). After mixing baseline volunteer plasma with a known concentration of cTn, there was appropriate recovery of cTn by both assays (Figure 2 , blue bars). In postbiotin samples mixed with cTn, four of five had more than a 10% decrease by the Gen 5 cTnT assay, including two falling to 19 ng/L or less, the upper reference limit of the assay (Figure 2 , red bars). In contrast, the contemporary cTnT assay levels did not decline significantly.
Simulation of Biotin Ingestion in Troponin-Positive Patients
❚Table 1❚ shows cTn levels measured by the Gen 5 cTnT and contemporary cTnT assays in 23 individual patient samples with and without spiking of known biotin concentrations using a pharmacokinetic-based simulation. Twenty-two of 23 baseline samples had abnormal cTn concentrations by both assays. In the presence of biotin, all 23 samples tested by the Gen 5 cTnT assay decreased more than 10%, indicating significant interference. Notably, 78% of the samples spiked with 140 ng/mL biotin, which simulates 1 hour after 10-mg ingestion, and 33% of samples spiked with 100 ng/mL biotin, which simulates 2 hours after 10-mg ingestion, decreased to or below the cTn upper reference limit of 19 ng/L. The contemporary cTnT assay had no clinically significant interference.
❚Table 2❚ shows cTn levels measured by the Gen 5 cTnT and hs-cTnI assays in an additional 16 individual patient samples. All baseline samples had abnormal cTn results by both assays. Biotin spiking led to more than a 10% decrease in all 16 samples tested by the Gen 5 cTnT assay. Twentyfive percent of these samples fell below the upper reference limit of 19 ng/L in the presence of 140 ng/mL plasma biotin.
❚Figure 1❚ Effect of short-term biotin consumption on plasma biotin levels. Plasma biotin levels were determined in five volunteers before the start of the study and after 5 days of taking a 10-mg/d dose ("postbiotin"). The hs-cTnI assay did not show significant underestimation in the presence of biotin at the concentrations tested. One sample (sample 11, postdose 2 hours) showed an overestimated cTnI result when spiked with 100 ng/mL biotin.
However, the same sample aliquots tested simultaneously at both higher (140 ng/mL) and lower biotin concentrations (50 ng/mL) had results comparable to their baseline value, suggesting the overestimation was likely a random error.
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❚Figure 2❚ Effect of short-term biotin consumption on troponin measurements determined by Gen 5 cardiac troponin T (cTnT) (A) and contemporary cTnT (B) assays in five healthy volunteers. Cardiac troponin (cTn) plasma levels were assessed from five healthy volunteers at baseline and after the same quantity of a known concentration of troponin was added to the baseline plasma and postbiotin plasma. *Indicates a more than 10% decrease in the cTn value. **Indicates a more than 10% decrease in cTn value at or below the upper reference limit (URL). LLD, lower limit of detection.
Assessment of Thresholds for Biotin Interference of Troponin Assays
The effects of a range of biotin concentrations on contemporary cTnT and Gen 5 cTnT assays differed substantially ❚Figure 3❚. The Gen 5 cTnT assay was susceptible to interference at plasma biotin concentrations of more than 31 ng/mL. The contemporary cTnT assay was susceptible to interference at plasma biotin concentrations of more than 315 ng/mL. Plasma biotin 500 ng/mL or more resulted in more than a 95% reduction of cTn in both assays. In contrast, the hs-cTnI assay had no significant interference from biotin at plasma concentrations up to 2,000 ng/mL.
Blocking Biotin Present in Samples
The addition of 50 µL streptavidin agarose beads effectively blocked the effects of plasma biotin concentrations up to 500 ng/mL on the performance of the Gen 5 TnT assay ❚Figure 4❚. The hs-cTnI assay did not have any interference from biotin, and addition of streptavidin did not have any detrimental effect on cTnI assay results.
Discussion
Our series of experiments show significant interference from biotin on the Gen 5 cTnT assay. We demonstrate a lower threshold of biotin interference with the Gen 5 cTnT assay (31 ng/mL) in comparison to biotin interference thresholds for contemporary cTnT (315 ng/ mL) and hs-cTnI (>2,000 ng/mL) assays. Our biotin consumption study in healthy volunteers and our biotin cTnT, cardiac troponin T; hs-cTnI, high-sensitivity cardiac troponin I. a Cardiac troponin-positive individual patient specimens received from the emergency department were tested after spiking with biotin concentrations reflecting predicted 1, 2, and 4 hours postdose plasma concentrations following a 10-mg/d dose taken consecutively for 5 days. Bold values indicate a more than 10% decrease in the cardiac troponin value compared to the control.
hs-cTnI hs-cTnI
❚Figure 3❚ Assessment of threshold for biotin interference in troponin assays. Dose-dependent inhibition of troponin values by biotin spiked into pooled, discarded cardiac troponin T (cTnT)-positive emergency department plasma specimens measured using contemporary cTnT (blue), Gen 5 cTnT (red), and high-sensitivity cardiac troponin I (hs-cTnI) (green) assays. Each dot is a single observation from one experiment, with two or more experiments for each assay. Dashed lines mark the biotin concentration that yields 10% inhibition (IC 10 ) of the troponin value. IC 10 and IC 50 values are reported.
simulation studies in cTnT-positive samples received from the ED confirmed a lower biotin tolerance threshold for the Gen 5 cTnT assay compared with the cTnT and hs-cTnI assays. Our findings suggest the Gen 5 cTnT assay is vulnerable to interference from OTC biotin ingestion at biotin doses used in the community. In contrast, the cTnT and hs-cTnI assays are not affected by biotin concentrations reflecting consumption of a 10-mg/d dose.
The difference in susceptibility of the Gen 5 cTnT assay compared with the cTnT assay is not fully understood. The manufacturer package insert has disclosed changes introduced in the Gen5 assay, including (1) increased volume of the specimen required (15 µL to 50 µL), (2) use of a new mouse/human chimeric monoclonal antibody recognizing cTnT conjugated to a ruthenium complex, and (3) increased concentrations of biotinylated monoclonal troponin T-specific antibody. The binding capacity of streptavidin for testing is not known, but the concentration of the streptavidin microparticles is the same in both assays (0.72 mg/mL). Because the Gen 5 assay requires a greater volume of plasma than the cTnT assay, this may contribute to greater susceptibility to biotin, as more molecules of biotin from the patient sample could potentially lead to more interference.
Prior studies have shown the potential impact of biotin interference at low biotin thresholds in thyroid panel assays. [9] [10] [11] [12] Our data suggest a similarly low biotin interference threshold for the Gen 5 cTnT assay. While the Gen 5 cTnT levels in the experiment largely were not significantly reclassified to normal (<6 ng/L), they were lowered below the 99th percentile threshold in 25% of test scenarios. These findings suggest the potential for a delay in diagnosis of MI in the presence of biotin concentrations achievable by OTC biotin use when using the Gen 5 cTnT assay. In addition, it is possible that natural clearance of plasma biotin levels in a patient with an abnormal baseline cTn may lead to the false suggestion of an upward trend in Gen 5 cTnT levels over time, which could mimic a trend concerning for an acute coronary syndrome.
Concerningly, there is theoretically a risk for false rule-out if a very short time frame is used for assessment. Protocols incorporating Gen 5 cTnT permit rule-out of MI in 0, 1, or 3 hours. 27 Indeed, according to the FDA advisory on biotin interference, a death attributable to a false rule-out of MI based on a falsely decreased cTn result has been reported. 3 We suggest longer rule-out times for acute MI cases with suspected biotin interference, in accordance with recommendations from the FDA and the assay manufacturer. With longer ruleout times, plasma biotin concentration is expected to decline based on pharmacokinetics modeling, interference would decrease over time, and thus serial Gen 5 cTnT measures would be expected to eventually identify those having an acute coronary syndrome, although at a significant delay.
In addition to increasing use of OTC biotin doses in the general population, application of mega doses of biotin (≥100 mg/d) in certain clinical conditions has also increased in recent years. 13 Hence, the FDA has mandated testing of all biotinylated assays in the presence of plasma biotin concentrations up to 1,200 ng/mL. This information is currently lacking in assay package inserts. In our study of plasma biotin concentrations up to 2,000 ng/ mL, we found that plasma biotin 500 ng/mL or more profoundly affected both the Gen 5 cTnT and cTnT assays. 4 The hs-cTnI assay was not affected by plasma biotin concentrations due to the lack of a streptavidin-biotin interaction step in its design.
The effects of biotin supplementation on plasma levels of biotin may be variable. Biotin levels measured
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❚Figure 4❚ Assessment of streptavidin pretreatment in blocking inhibitory effects of biotin. Pooled cardiac troponin (cTn)-positive patient samples were spiked with known concentrations of biotin (100 and 500 ng/mL) without streptavidin pretreatment (blue symbols) and with streptavidin pretreatment (red symbols). Specimens were centrifuged and the supernatant cTn levels were determined with the Gen 5-cTnT (A) and high-sensitivity cardiac troponin I (hs-cTnI) (B) assays. Each symbol is the mean ± standard deviation of three different pools. from five volunteers in this study after ingestion of biotin ranged from 10 to 109 ng/mL ( Figure 1A ). The variability is likely explained by individual variations in pharmacokinetic parameters (eg, absorption, metabolism, and excretion) of the supplemental biotin. The variability in the levels 2 hours postingestion directly affected the cTnT recovery study (Figure 2A) , with no effect in volunteer 1 and a smaller effect in volunteer 3 compared with volunteers 2, 4, and 5. Given the variability of biotin levels even within a small study of five volunteers, it will therefore be critical to understand the usage patterns of biotin in the community to estimate the potential clinical impact of biotin interference on the Gen 5 cTnT assay. One recently reported study from a single site found that as much as 7% of their ED population had biotin levels that were more than 10 ng/mL; only 0.5% had levels that would have interfered with the Gen 5 troponin assay. 28 Manufacturer-recommended washout periods for other biotin-affected assays are impractical for MI assessment. 13 Also concerning is the potential lack of awareness of biotin ingestion in the general population, as well as the potential for interference with diagnostic tests in clinical practice. 3 Laboratories should carefully examine potential effects of biotin on immunoassays used in practice.
In cases where the use of biotinylated assays cannot be avoided, we suggest detailed history taking for OTC supplements in patients presenting with chest pain to centers using the Gen 5 cTnT assay. Streptavidin and other biotin-blocking strategies can be used for investigating biotin interference in irreplaceable samples; however, this also results in a significant delay, as our work and others require incubation of 45 to 60 minutes. 24, 25 Further efforts to decrease incubation times for streptavidin pretreatment may be helpful. In addition, we suggest the manufacturer work to increase the biotin tolerance levels or convert them to a nonbiotinylated assay. Finally, we suggest that health care systems using this assay should educate ordering providers of the potential for biotin interference in Gen 5 cTnT measurement.
Limitations
We did not identify and evaluate cTn levels from patients with possible MI who were known to take biotin supplements. We did not collect serial specimens or evaluate how cTn and biotin levels change serially. Such studies will require prospective assessment in patients seeking treatment for chest pain at the ED. Animal models may provide some insight on this dynamic but were beyond the scope of the present work. We did not measure biotin levels in plasmas that we spiked with reagent biotin to confirm the accuracy of the amount added; doing so for each concentration tested was cost-prohibitive. Some sample volumes were insufficient to run all three simulations of plasma biotin concentrations. Finally, we did not have access to the hs-cTnI assay at the time of our initial experiments comparing cTnT with Gen 5 cTnT, so the hs-cTnI studies were not performed on the same samples.
Conclusion
Our findings support the caution advised by the FDA regarding the impact of biotin on some cTn measurements, particularly with the Gen 5 cTnT assay, where the tolerance for biotin interference is lowest. Determining the prevalence of high biotin use across the population will be instrumental in understanding the potential clinical impact of biotin interference.
